Notice: Undefined index: HTTP_ACCEPT_LANGUAGE in C:\inetpub\wwwroot\technology_detail.php on line 331
 Technology Detail


The Office of Technology Licensing was established in 1970 to transfer technologies developed at Stanford. Find out more about OTL's history, mission, staff, and statistics.

Login to TechFinder » 

Using E.coli Im9 as an Immune Stimulator


Stanford Reference:

06-320


Abstract


Stanford researchers have discovered that the small and stable E.coli protein, IM9, is a potent stimulator of the mammalian immune system. This discovery is particularly useful for increasing the potency of fusion protein vaccines. The patent application for this invention describes polypeptide compositions that increase immunogenicity, and methods of use thereof, where the immune response of a mammalian host to an antigen of interest is increased by co-formulation of the antigen with a bacterial immunity protein.


Applications


  • To elicit stronger immune responses from fusion protein vaccines.

Advantages


  • Provides significantly stronger immune response as judged by higher antibody titers and better protection against lymphoma tumor challenge
  • Novel use of protein as an immune stimulant

Publications



Related Web Links



Innovators & Portfolio



Patent Status



Date Released

 6/28/2016
 

Licensing Contact


Irit Gal, Senior Licensing Associate
650-723-1586 (Business)
Login to Request Information

[-] Map/Timeline

92-045 Novel Endothelial Adhesion Molecule for Monocytes: L11-CD43
92-146 Achieving B-Cell Lymphoma Growth Modulation and Enhanced Tumor Resistance Using Idiotype/Cytokine Conjugates
93-077 A Novel Protein and Gene Expressed by Human T Cells and Monocytes: Alloreaction-Associated Antigen (ARAg)

more technologies »

Related Keywords


B-cell immunology   protein biotherapeutics   top pharma companies   immunization   protein therapeutics   immune   infectious   cancer immunotherapy   adjuvant   therapeutic: immunotherapy   therapeutic: proteins   research tool: protein synthesis   cancer: lymphoma   lymphoma   therapeutic: vaccine   therapeutic: anticancer   cancer vaccine   protein folding   06-320   
 

   

  

Also of Interest...
92-045 Novel Endothelial Adhesion Molecule for Monocytes: L11-CD43
92-146 Achieving B-Cell Lymphoma Growth Modulation and Enhanced Tumor Resistance Using Idiotype/Cytokine Conjugates
93-077 A Novel Protein and Gene Expressed by Human T Cells and Monocytes: Alloreaction-Associated Antigen (ARAg)

Recently Viewed...
S06-320 Using E.coli Im9 as an Immune Stimulator